Press-release for stocks publishing date 2022 - 02

Prices are updated after-hours

publishing date : 2022 - 02 - 16 tags : Therapeutics

save search

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
Published: 2022-02-16 (Crawled : 23:00) - biospace.com/
MRKR | $4.25 3.65% 3.52% 15K

Consumer Services

| 603.72% | O: 5.39% H: 1.4% C: -0.4%
expansion program therapeutics

AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
Published: 2022-02-16 (Crawled : 22:00) - biospace.com/
ANTX | $2.43 2.1% 2.06% 100K

| Email alert Add to watchlist
treatment drug bacteria granted therapeutics drug designation orphan drug infection grant designation infections

Aimmune Therapeutics Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for up to 2 Years in the Journal of Allergy and Clinical Immunology
Published: 2022-02-16 (Crawled : 19:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K

Manufacturing

| Email alert Add to watchlist
palforzia treatment ces therapeutics immunology

Star Therapeutics Starts a Family with Electra
Published: 2022-02-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -12.67% | O: -0.08% H: 1.53% C: 1.04%
star therapeutics

Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
Published: 2022-02-16 (Crawled : 15:00) - biospace.com/
ENDV | $0.0028 158.07% 74K

Professional, Scientific, and T...

| -81.18% | O: 5.29% H: 0.0% C: -5.03%
ces therapeutics group

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
SPRO | $1.41 -4.08% -4.26% 380K

Health Technology

| -85.97% | O: 2.1% H: 0.0% C: -5.69%
spr206 trial therapeutics phase 1 topline results positive topline phase 2 phase 3

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology

| -12.84% | O: -0.07% H: 0.59% C: 0.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -11.6% | O: -0.49% H: 0.81% C: 0.43%
ARCT 4 | $25.995 -1.23% -1.25% 630K

Health Technology

| 4.55% | O: -2.58% H: 1.98% C: 1.07%
financial results therapeutics report results

Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
Published: 2022-02-16 (Crawled : 14:00) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M

Health Technology

| -65.95% | O: 0.69% H: 0.0% C: -0.97%
financial results therapeutics report results

Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research
Published: 2022-02-16 (Crawled : 13:30) - biospace.com/
BTTX | $0.009 -65.02% 180K

| -99.74% | O: -1.24% H: 1.25% C: -1.96%
research therapeutics enroll

Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
Published: 2022-02-16 (Crawled : 13:30) - biospace.com/
HZNP | $116.3 0.03% 29M

Health Technology

| 18.47% | O: -0.4% H: 0.46% C: -0.08%
therapeutics

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K

Health Technology

| -85.97% | O: 2.1% H: 0.0% C: -5.69%
spr206 treatment xin drug trial therapeutics phase 1 topline results positive topline infection negative iot set infections

CytomX Therapeutics Announces New Employment Inducement Grants
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
CTMX | $1.67 -3.47% -3.59% 510K

Health Technology

| -59.07% | O: 0.25% H: 2.2% C: 0.98%
therapeutics grant granted

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M

Health Technology

| -87.35% | O: -1.53% H: 0.29% C: -3.46%
financial results conference therapeutics report results

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
Published: 2022-02-16 (Crawled : 13:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M

Health Technology

| -69.36% | O: -16.67% H: 5.38% C: -0.94%
BIIB | $194.39 2.03% 1.99% 1.6M

Health Technology

| -10.58% | O: -0.29% H: 0.0% C: -1.01%
therapeutics phase 3

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -12.67% | O: -0.08% H: 1.53% C: 1.04%
rare star therapeutics disease 100 merge

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
EQ | $1.63 -5.78% -6.13% 100K

Health Technology

| -59.75% | O: 0.0% H: 5.0% C: 4.25%
drug therapeutics

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
Published: 2022-02-16 (Crawled : 12:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K

Finance

| 40.23% | O: -0.03% H: 0.0% C: -2.82%
day financial results therapeutics report results

Centauri Therapeutics Closes £24 Million GBP Series A Investment Round
Published: 2022-02-16 (Crawled : 11:00) - biospace.com/
EVOTF | $21.68 30.35% 3.2K

Health Technology

| Email alert Add to watchlist
therapeutics